Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Why Clover Health’s latest earnings matter for shareholders
Clover Health Investments (CLOV) sparked fresh attention after first quarter 2026 results showed a return to profitability, with US$27.3 million in net income and Medicare Advantage membership reaching about 156,000 members.
See our latest analysis for Clover Health Investments.
The strong first quarter has come alongside a sharp shift in sentiment, with a 48.4% 30 day share price return and a 32.4% 90 day share price return, contrasting with a 24.8% total shareholder return decline over the past year and a 196.8% total shareholder return over three years.
If Clover Health’s use of technology in Medicare Advantage caught your eye, this is a good moment to look across healthcare related AI opportunities using our 35 healthcare AI stocks
With the stock up 48.4% in a month and trading close to analyst targets, yet screening as materially below some intrinsic value estimates, investors now need to ask whether there is still a buying opportunity or whether the market is already pricing in future growth.
Most Popular Narrative: 10% Overvalued
With Clover Health trading at $2.82 against a narrative fair value of $2.82, the widely followed model views the stock as slightly overvalued once the 10% premium to fair value is included.
The analysts have a consensus price target of $2.82 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.2, and the most bearish reporting a price target of just $2.5.
Want to see what is really driving that fair value figure? The narrative places significant weight on rapid earnings improvement and richer margins in its long-range forecasts.
Result: Fair Value of $2.82 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, investors still need to watch rising medical and pharmacy utilization, as well as the risk that any Medicare Advantage reimbursement or policy changes could pressure margins and earnings.
Find out about the key risks to this Clover Health Investments narrative.
Another way to look at valuation
Analysts see Clover Health as roughly 10% overvalued at $2.82 versus their $2.82 fair value, but the price based on sales tells a different story. The stock trades on a P/S of 0.7x versus 1.2x for the US Healthcare industry and 1.9x for peers, while the fair ratio sits at 0.8x. That gap suggests the multiple could still move either up toward peers or down toward the fair ratio, so which outcome do you think is more realistic for this business?
See what the numbers say about this price — find out in our valuation breakdown.
NasdaqGS:CLOV P/S Ratio as at May 2026 Next Steps
With sentiment clearly mixed after such a sharp move in the share price, this is the time to look closely at the numbers, weigh both sides of the story and form your own view using our 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with just one stock, you could miss opportunities that better suit your goals, risk comfort and income needs across different parts of the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CLOV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com